Drug reference
idecabtagene vicleucel
CAR T cell therapy (BCMA-targeted) · anticancer, cellular therapy
CAR T cell therapy (BCMA-targeted)anticancer, cellular therapy
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Idecabtagene vicleucel is an anti-BCMA CAR T immunotherapy.
Indications
multiple myeloma (MM)Relapsed multiple myeloma (after at least two prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody)
Side effects
Serious
- Cytokine release syndrome
- Neurotoxicity
Related guidelines
Ask House about idecabtagene vicleucel
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team